Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Adams, GP; Weiner, LM
   Radioimmunotherapy of solid tumors: From fairytale to reality
   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
   
   G.P. Adams e L.M. Weiner, "Radioimmunotherapy of solid tumors: From fairytale to reality", CANC BIO R, 16(1), 2001, pp. 9-11
2. von Mehren, M; Arlen, P; Gulley, J; Rogatko, A; Cooper, HS; Meropol, NJ; Alpaugh, RK; Davey, M; McLaughlin, S; Beard, MT; Tsang, KY; Schlom, J; Weiner, LM
   The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma
   CLINICAL CANCER RESEARCH
   
   M. von Mehren et al., "The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma", CLIN CANC R, 7(5), 2001, pp. 1181-1191
3. O'Dwyer, PJ; Manola, J; Valone, FH; Ryan, LM; Hines, JD; Wadler, S; Haller, DG; Arbuck, SG; Weiner, LM; Mayer, RJ; Benson, AB
   Fluorouracil modulation in colorectal cancer: Lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B study
   JOURNAL OF CLINICAL ONCOLOGY
   
   P.J. O'Dwyer et al., "Fluorouracil modulation in colorectal cancer: Lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B study", J CL ONCOL, 19(9), 2001, pp. 2413-2421
4. Schilder, RJ; Gallo, JM; Millenson, MM; Bookman, MA; Weiner, LM; Rogatko, A; Rogers, B; Padavic-Shallers, K; Boente, M; Rosenblum, N; Adams, AL; Ciccotto, S; Ozols, RF
   Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, andtopotecan with peripheral-blood stem-cell support as front-line therapy
   JOURNAL OF CLINICAL ONCOLOGY
   
   R.J. Schilder et al., "Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, andtopotecan with peripheral-blood stem-cell support as front-line therapy", J CL ONCOL, 19(4), 2001, pp. 1183-1194
5. Pandya, KJ; Yeap, BY; Weiner, LM; Krook, JE; Erban, JK; Schinella, RA; Davis, TE
   Megestrol and tamoxifen in patients with advanced endometrial cancer - An Eastern Cooperative Oncology Group study (E4882)
   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
   
   K.J. Pandya et al., "Megestrol and tamoxifen in patients with advanced endometrial cancer - An Eastern Cooperative Oncology Group study (E4882)", AM J CL ONC, 24(1), 2001, pp. 43-46
6. McCall, AM; Shahied, L; Amoroso, AR; Horak, EM; Simmons, HH; Nielson, U; Adams, GP; Schier, R; Marks, JD; Weiner, LM
   Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity
   JOURNAL OF IMMUNOLOGY
   
   A.M. McCall et al., "Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity", J IMMUNOL, 166(10), 2001, pp. 6112-6117
7. Powers, DB; Amersdorfer, P; Poul, MA; Nielsen, UB; Shalaby, MR; Adams, GP; Weiner, LM; Marks, JD
   Expression of single-chain Fv-Fc fusions in Pichia pastoris
   JOURNAL OF IMMUNOLOGICAL METHODS
   
   D.B. Powers et al., "Expression of single-chain Fv-Fc fusions in Pichia pastoris", J IMMUNOL M, 251(1-2), 2001, pp. 123-135
8. Segal, DM; Weiner, GJ; Weiner, LM
   Introduction: bispecific antibodies
   JOURNAL OF IMMUNOLOGICAL METHODS
   
   D.M. Segal et al., "Introduction: bispecific antibodies", J IMMUNOL M, 248(1-2), 2001, pp. 1-6
9. Adams, GP; Schier, R; McCall, AM; Simmons, HH; Horak, EM; Alpaugh, RK; Marks, JD; Weiner, LM
   High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules
   CANCER RESEARCH
   
   G.P. Adams et al., "High affinity restricts the localization and tumor penetration of single-chain Fv antibody molecules", CANCER RES, 61(12), 2001, pp. 4750-4755
10. De Ferrari, GV; Canales, MA; Shin, I; Weiner, LM; Silman, I; Inestrosa, NC
    A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation
    BIOCHEMISTRY
    
    G.V. De Ferrari et al., "A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation", BIOCHEM, 40(35), 2001, pp. 10447-10457
11. Weiner, LM
    Bispecific antibodies in cancer therapy
    CANCER JOURNAL
    
    L.M. Weiner, "Bispecific antibodies in cancer therapy", CANCER J, 6, 2000, pp. S265-S271
12. Hudes, GR; Szarka, CE; Adams, A; Ranganathan, S; McCauley, RA; Weiner, LM; Langer, CJ; Litwin, S; Yeslow, G; Halberr, T; Qian, MX; Gallo, JM
    Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patientswith refractory solid malignancies
    CLINICAL CANCER RESEARCH
    
    G.R. Hudes et al., "Phase I pharmacokinetic trial of perillyl alcohol (NSC 641066) in patientswith refractory solid malignancies", CLIN CANC R, 6(8), 2000, pp. 3071-3080
13. von Mehren, M; Arlen, P; Tsang, KY; Rogatko, A; Meropol, N; Cooper, HS; Davey, M; McLaughlin, S; Schlom, J; Weiner, LM
    Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas
    CLINICAL CANCER RESEARCH
    
    M. von Mehren et al., "Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas", CLIN CANC R, 6(6), 2000, pp. 2219-2228
14. Knox, SJ; Goris, ML; Tempero, M; Weiden, PL; Gentner, L; Breitz, H; Adams, GP; Axworthy, D; Gaffigan, S; Bryan, K; Fisher, DR; Colcher, D; Horak, ID; Weiner, LM
    Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer
    CLINICAL CANCER RESEARCH
    
    S.J. Knox et al., "Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer", CLIN CANC R, 6(2), 2000, pp. 406-414
15. Adams, GP; Shaller, CC; Chappell, LL; Wu, C; Horak, EM; Simmons, HH; Litwin, S; Marks, JD; Weiner, LM; Brechbiel, MW
    Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules
    NUCLEAR MEDICINE AND BIOLOGY
    
    G.P. Adams et al., "Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules", NUCL MED BI, 27(4), 2000, pp. 339-346
16. Weiner, LM; Adams, GP
    New approaches to antibody therapy
    ONCOGENE
    
    L.M. Weiner e G.P. Adams, "New approaches to antibody therapy", ONCOGENE, 19(53), 2000, pp. 6144-6151
17. Nielsen, UB; Adams, GP; Weiner, LM; Marks, JD
    Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cellsis independent of the intrinsic antibody affinity
    CANCER RESEARCH
    
    U.B. Nielsen et al., "Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cellsis independent of the intrinsic antibody affinity", CANCER RES, 60(22), 2000, pp. 6434-6440
18. von Mehren, M; Weiner, LM
    Breast cancer: Biologic therapy
    STRATEGIES IN ADJUVANT THERAPY
    
    M. von Mehren e L.M. Weiner, "Breast cancer: Biologic therapy", STRATEGIES IN ADJUVANT THERAPY, 2000, pp. 203-232
19. Segal, DM; Weiner, GJ; Weiner, LM
    Bispecific antibodies in cancer therapy
    CURRENT OPINION IN IMMUNOLOGY
    
    D.M. Segal et al., "Bispecific antibodies in cancer therapy", CURR OP IM, 11(5), 1999, pp. 558-562
20. Amoroso, AR; Alpaugh, RK; Barth, MW; McCall, AM; Weiner, LM
    Production and characterization of mice transgenic for the A and B isoforms of human Fc gamma RIII
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    A.R. Amoroso et al., "Production and characterization of mice transgenic for the A and B isoforms of human Fc gamma RIII", CANCER IMMU, 48(8), 1999, pp. 443-455
21. McCall, AM; Adams, GP; Amoroso, AR; Nielsen, UB; Zhang, L; Horak, E; Simmons, H; Schier, R; Marks, JD; Weiner, LM
    Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis
    MOLECULAR IMMUNOLOGY
    
    A.M. McCall et al., "Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis", MOL IMMUNOL, 36(7), 1999, pp. 433-445
22. Weiner, LM
    Monoclonal antibody therapy of cancer
    SEMINARS IN ONCOLOGY
    
    L.M. Weiner, "Monoclonal antibody therapy of cancer", SEMIN ONCOL, 26(5), 1999, pp. 43-51
23. Weiner, LM
    An overview of monoclonal antibody therapy of cancer
    SEMINARS IN ONCOLOGY
    
    L.M. Weiner, "An overview of monoclonal antibody therapy of cancer", SEMIN ONCOL, 26(4), 1999, pp. 41-50
24. Weiner, LM
    Paclitaxel in the treatment of esophageal cancer
    SEMINARS IN ONCOLOGY
    
    L.M. Weiner, "Paclitaxel in the treatment of esophageal cancer", SEMIN ONCOL, 26(1), 1999, pp. 106-108
25. Alpaugh, RK; von Mehren, M; Palazzo, I; Atkins, MB; Sparano, JA; Schuchter, L; Weiner, LM; Dutcher, JP
    Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon
    MEDICAL ONCOLOGY
    
    R.K. Alpaugh et al., "Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon", MED ONCOL, 15(3), 1998, pp. 191-198
26. ALPAUGH RK; SCHULTZ J; MCALEER C; GIANTONIO BJ; PERSSON R; BURNITE M; NIELSEN SE; VITEK L; PERSSON B; WEINER LM
    SUPERANTIGEN-TARGETED THERAPY - PHASE-I ESCALATING REPEAT DOSE TRIAL OF THE FUSION PROTEIN PNU-214565 IN PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES
    Clinical cancer research
    
    R.K. Alpaugh et al., "SUPERANTIGEN-TARGETED THERAPY - PHASE-I ESCALATING REPEAT DOSE TRIAL OF THE FUSION PROTEIN PNU-214565 IN PATIENTS WITH ADVANCED GASTROINTESTINAL MALIGNANCIES", Clinical cancer research, 4(8), 1998, pp. 1903-1914
27. MOVSAS B; HANLON AL; LANCIANO R; SCHER RM; WEINER LM; SIGURDSON ER; HOFFMAN JP; EISENBERG BL; COOPER HS; PROVINS S; COIA LR
    PHASE-I DOSE ESCALATING TRIAL OF HYPERFRACTIONATED PREOPERATIVE CHEMORADIATION FOR LOCALLY ADVANCED RECTAL-CANCER
    International journal of radiation oncology, biology, physics
    
    B. Movsas et al., "PHASE-I DOSE ESCALATING TRIAL OF HYPERFRACTIONATED PREOPERATIVE CHEMORADIATION FOR LOCALLY ADVANCED RECTAL-CANCER", International journal of radiation oncology, biology, physics, 42(1), 1998, pp. 43-50
28. ALPAUGH RK; WEINER LM; PERSSON R; PERSSON B
    OVERVIEW OF CLINICAL-TRIALS EMPLOYING ANTIBODY-TARGETED SUPERANTIGENS
    Advanced drug delivery reviews
    
    R.K. Alpaugh et al., "OVERVIEW OF CLINICAL-TRIALS EMPLOYING ANTIBODY-TARGETED SUPERANTIGENS", Advanced drug delivery reviews, 31(1-2), 1998, pp. 143-152
29. ADAMS GP; SCHIER R; MARSHALL K; WOLF EJ; MCCALL AM; MARKS JD; WEINER LM
    INCREASED AFFINITY LEADS TO IMPROVED SELECTIVE TUMOR DELIVERY OF SINGLE-CHAIN FV ANTIBODIES
    Cancer research
    
    G.P. Adams et al., "INCREASED AFFINITY LEADS TO IMPROVED SELECTIVE TUMOR DELIVERY OF SINGLE-CHAIN FV ANTIBODIES", Cancer research, 58(3), 1998, pp. 485-490
30. KELLER SM; RYAN LM; COIA LR; DANG P; VAUGHT DJ; DIGGS C; WEINER LM; BENSON AB
    HIGH-DOSE CHEMORADIOTHERAPY FOLLOWED BY ESOPHAGECTOMY FOR ADENOCARCINOMA OF THE ESOPHAGUS AND GASTROESOPHAGEAL JUNCTION - RESULTS OF A PHASE-II STUDY OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP
    Cancer
    
    S.M. Keller et al., "HIGH-DOSE CHEMORADIOTHERAPY FOLLOWED BY ESOPHAGECTOMY FOR ADENOCARCINOMA OF THE ESOPHAGUS AND GASTROESOPHAGEAL JUNCTION - RESULTS OF A PHASE-II STUDY OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP", Cancer, 83(9), 1998, pp. 1908-1916
31. ADAMS GP; SCHIER R; MCCALL AM; CRAWFORD RS; WOLF EJ; WEINER LM; MARKS JD
    PROLONGED IN-VIVO TUMOR RETENTION OF A HUMAN DIABODY TARGETING THE EXTRACELLULAR DOMAIN OF HUMAN HER2 NEU/
    British Journal of Cancer
    
    G.P. Adams et al., "PROLONGED IN-VIVO TUMOR RETENTION OF A HUMAN DIABODY TARGETING THE EXTRACELLULAR DOMAIN OF HUMAN HER2 NEU/", British Journal of Cancer, 77(9), 1998, pp. 1405-1412
32. LATTANZI JP; COIA LR; SCHER RM; ENGSTROM PF; HOFFMAN JP; EISENBERG BF; SIGURSDSON ER; EPSTEIN BE; WEINER LM
    A PROSPECTIVE PHASE I II STUDY OF INTRAARTERIAL CHEMOTHERAPY AND ESCALATING DOSES OF RADIATION-THERAPY FOR SURGICALLY UNRESECTABLE CARCINOMA CONFINED TO THE LIVER/
    GI cancer
    
    J.P. Lattanzi et al., "A PROSPECTIVE PHASE I II STUDY OF INTRAARTERIAL CHEMOTHERAPY AND ESCALATING DOSES OF RADIATION-THERAPY FOR SURGICALLY UNRESECTABLE CARCINOMA CONFINED TO THE LIVER/", GI cancer, 2(2), 1997, pp. 111-117
33. PERETZ M; WEINER LM; BURSTEIN Y
    CYSTEINE REACTIVITY IN THERMOANAEROBACTER-BROCKII ALCOHOL-DEHYDROGENASE
    Protein science
    
    M. Peretz et al., "CYSTEINE REACTIVITY IN THERMOANAEROBACTER-BROCKII ALCOHOL-DEHYDROGENASE", Protein science, 6(5), 1997, pp. 1074-1083
34. NIELSEN SE; ZEUTHEN J; PERSSON B; SVEDBERG A; PERSSON R; WEINER LM; HANSEN HH
    A PHASE-I TRIAL OF ESCALATING REPEATED DOSES OF PNU-214565 IN PATIENTS WITH ADVANCED COLORECTAL AND OTHER GASTROINTESTINAL ADENOCARCINOMAS
    European journal of cancer
    
    S.E. Nielsen et al., "A PHASE-I TRIAL OF ESCALATING REPEATED DOSES OF PNU-214565 IN PATIENTS WITH ADVANCED COLORECTAL AND OTHER GASTROINTESTINAL ADENOCARCINOMAS", European journal of cancer, 33, 1997, pp. 383-383
35. GIANTONIO BJ; ALPAUGH RK; SCHULTZ J; MCALEER C; NEWTON DW; SHANNON B; GUEDEZ Y; KOTB M; VITEK L; PERSSON R; GUNNARSSON PO; KALLAND T; DOHLSTEN M; PERSSON B; WEINER LM
    SUPERANTIGEN-BASED IMMUNOTHERAPY - A PHASE-I TRIAL OF PNU-214565, A MONOCLONAL-ANTIBODY STAPHYLOCOCCAL-ENTEROTOXIN A RECOMBINANT FUSION PROTEIN, IN ADVANCED PANCREATIC AND COLORECTAL-CANCER
    Journal of clinical oncology
    
    B.J. Giantonio et al., "SUPERANTIGEN-BASED IMMUNOTHERAPY - A PHASE-I TRIAL OF PNU-214565, A MONOCLONAL-ANTIBODY STAPHYLOCOCCAL-ENTEROTOXIN A RECOMBINANT FUSION PROTEIN, IN ADVANCED PANCREATIC AND COLORECTAL-CANCER", Journal of clinical oncology, 15(5), 1997, pp. 1994-2007
36. MOVSAS B; HANLON AL; LANCIANO RM; SCHER RM; WEINER LM; SIGURDSON ER; HOFFMAN JP; COOPER HS; PROVINS S; COIA LR
    PHASE-I DOSE ESCALATING TRIAL OF HYPERFRACTINATED PREOPERATIVE CHEMORADIATION FOR LOCALLY ADVANCED RECTAL-CANCER
    International journal of radiation oncology, biology, physics
    
    B. Movsas et al., "PHASE-I DOSE ESCALATING TRIAL OF HYPERFRACTINATED PREOPERATIVE CHEMORADIATION FOR LOCALLY ADVANCED RECTAL-CANCER", International journal of radiation oncology, biology, physics, 39(2), 1997, pp. 168-168
37. WEINER LM; ALPAUGH RK; VONMEHREN M
    REDIRECTED CELLULAR CYTOTOXICITY EMPLOYING BISPECIFIC ANTIBODIES AND OTHER MULTIFUNCTIONAL BINDING-PROTEINS
    Cancer immunology and immunotherapy
    
    L.M. Weiner et al., "REDIRECTED CELLULAR CYTOTOXICITY EMPLOYING BISPECIFIC ANTIBODIES AND OTHER MULTIFUNCTIONAL BINDING-PROTEINS", Cancer immunology and immunotherapy, 45(3-4), 1997, pp. 190-192
38. CLARK JI; ALPAUGH RK; VONMEHREN M; SCHULTZ J; GRALOW JR; CHEEVER MA; RING DB; WEINER LM
    INDUCTION OF MULTIPLE ANTI-C-ERB-2 SPECIFICITIES ACCOMPANIES A CLASSICAL IDIOTYPIC CASCADE FOLLOWING 2B1 BISPECIFIC MONOCLONAL-ANTIBODY TREATMENT
    Cancer immunology and immunotherapy
    
    J.I. Clark et al., "INDUCTION OF MULTIPLE ANTI-C-ERB-2 SPECIFICITIES ACCOMPANIES A CLASSICAL IDIOTYPIC CASCADE FOLLOWING 2B1 BISPECIFIC MONOCLONAL-ANTIBODY TREATMENT", Cancer immunology and immunotherapy, 44(5), 1997, pp. 265-272
39. WEINER LM; COLARUSSO P; GOLDBERG M; DRESLER C; COIA LR
    COMBINED-MODALITY THERAPY FOR ESOPHAGEAL CANCER - PHASE-I TRIAL OF ESCALATING DOSES OF PACLITAXEL IN COMBINATION WITH CISPLATIN, 5-FLUOROURACIL, AND HIGH-DOSE RADIATION BEFORE ESOPHAGECTOMY
    Seminars in oncology
    
    L.M. Weiner et al., "COMBINED-MODALITY THERAPY FOR ESOPHAGEAL CANCER - PHASE-I TRIAL OF ESCALATING DOSES OF PACLITAXEL IN COMBINATION WITH CISPLATIN, 5-FLUOROURACIL, AND HIGH-DOSE RADIATION BEFORE ESOPHAGECTOMY", Seminars in oncology, 24(6), 1997, pp. 93-95
40. SHIN I; SILMAN I; WEINER LM
    INTERACTION OF PARTIALLY UNFOLDED FORMS OF TORPEDO ACETYLCHOLINESTERASE WITH LIPOSOMES
    Protein science
    
    I. Shin et al., "INTERACTION OF PARTIALLY UNFOLDED FORMS OF TORPEDO ACETYLCHOLINESTERASE WITH LIPOSOMES", Protein science, 5(1), 1996, pp. 42-51
41. WEINER LM; ALPAUGH RK; AMOROSO AR; ADAMS GP; RING DB; BARTH MW
    HUMAN NEUTROPHIL INTERACTIONS OF A BISPECIFIC MONOCLONAL-ANTIBODY TARGETING TUMOR AND HUMAN FC-GAMMA-RIII
    Cancer immunology and immunotherapy
    
    L.M. Weiner et al., "HUMAN NEUTROPHIL INTERACTIONS OF A BISPECIFIC MONOCLONAL-ANTIBODY TARGETING TUMOR AND HUMAN FC-GAMMA-RIII", Cancer immunology and immunotherapy, 42(3), 1996, pp. 141-150
42. GEORGE AJT; JAMAR F; TAI MS; HEELAN BT; ADAMS GP; MCCARTNEY JE; HOUSTON LL; WEINER LM; OPPERMANN H; PETERS AM; HUSTON JS
    RADIOMETAL LABELING OF RECOMBINANT PROTEINS BY A GENETICALLY-ENGINEERED MINIMAL CHELATION SITE - TC-99M COORDINATION BY SINGLE-CHAIN FV ANTIBODY FUSION PROTEINS THROUGH A C-TERMINAL CYSTEINYL PEPTIDE (VOL 92, PG 8358, 1995)
    Proceedings of the National Academy of Sciences of the United Statesof America
    
    A.J.T. George et al., "RADIOMETAL LABELING OF RECOMBINANT PROTEINS BY A GENETICALLY-ENGINEERED MINIMAL CHELATION SITE - TC-99M COORDINATION BY SINGLE-CHAIN FV ANTIBODY FUSION PROTEINS THROUGH A C-TERMINAL CYSTEINYL PEPTIDE (VOL 92, PG 8358, 1995)", Proceedings of the National Academy of Sciences of the United Statesof America, 93(18), 1996, pp. 9991-9991
43. SCHIER R; BYE J; APELL G; MCCALL A; ADAMS GP; MALMQVIST M; WEINER LM; MARKS JD
    ISOLATION OF HIGH-AFFINITY MONOMERIC HUMAN ANTI-C-ERBB-2 SINGLE-CHAINFV USING AFFINITY-DRIVEN SELECTION
    Journal of Molecular Biology
    
    R. Schier et al., "ISOLATION OF HIGH-AFFINITY MONOMERIC HUMAN ANTI-C-ERBB-2 SINGLE-CHAINFV USING AFFINITY-DRIVEN SELECTION", Journal of Molecular Biology, 255(1), 1996, pp. 28-43
44. PINKUS R; WEINER LM; DANIEL V
    ROLE OF OXIDANTS AND ANTIOXIDANTS IN THE INDUCTION OF AP-1, NF-KAPPA-B, AND GLUTATHIONE-S-TRANSFERASE GENE-EXPRESSION
    The Journal of biological chemistry
    
    R. Pinkus et al., "ROLE OF OXIDANTS AND ANTIOXIDANTS IN THE INDUCTION OF AP-1, NF-KAPPA-B, AND GLUTATHIONE-S-TRANSFERASE GENE-EXPRESSION", The Journal of biological chemistry, 271(23), 1996, pp. 13422-13429
45. AMOROSO AR; CLARK JI; LITWIN S; HSIEHMA S; SHI T; ALPAUGH RK; ADAMS GP; WOLF EJ; RING DB; WEINER LM
    BINDING CHARACTERISTICS AND ANTITUMOR PROPERTIES OF 1A10 BISPECIFIC ANTIBODY RECOGNIZING GP40 AND HUMAN TRANSFERRIN RECEPTOR
    Cancer research
    
    A.R. Amoroso et al., "BINDING CHARACTERISTICS AND ANTITUMOR PROPERTIES OF 1A10 BISPECIFIC ANTIBODY RECOGNIZING GP40 AND HUMAN TRANSFERRIN RECEPTOR", Cancer research, 56(1), 1996, pp. 113-120
46. MUNN DH; BREE AG; BEALL AC; KAVIANI MD; SABIO H; SCHAUB RG; ALPAUGH RK; WEINER LM; GOLDMAN SJ
    RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR IN NONHUMAN-PRIMATES - SELECTIVE EXPANSION OF A CD16(-KILLER-CELLS() MONOCYTE SUBSETWITH PHENOTYPIC SIMILARITY TO PRIMATE NATURAL)
    Blood
    
    D.H. Munn et al., "RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR IN NONHUMAN-PRIMATES - SELECTIVE EXPANSION OF A CD16(-KILLER-CELLS() MONOCYTE SUBSETWITH PHENOTYPIC SIMILARITY TO PRIMATE NATURAL)", Blood, 88(4), 1996, pp. 1215-1224
47. KRIGEL RL; PADAVICSHALLER K; TOOMEY C; COMIS RL; WEINER LM
    PHASE-I STUDY OF SEQUENTIALLY ADMINISTERED RECOMBINANT TUMOR-NECROSIS-FACTOR AND RECOMBINANT INTERLEUKIN-2
    Journal of immunotherapy with emphasis on tumor immunology
    
    R.L. Krigel et al., "PHASE-I STUDY OF SEQUENTIALLY ADMINISTERED RECOMBINANT TUMOR-NECROSIS-FACTOR AND RECOMBINANT INTERLEUKIN-2", Journal of immunotherapy with emphasis on tumor immunology, 17(3), 1995, pp. 161-170
48. LANGER CJ; CATALANO R; WEINER LM; SCHER R; BAGCHI P; SAREN B; COMIS RL
    PHASE-II EVALUATION OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN (M-VAC) IN ADVANCED, MEASURABLE BREAST-CARCINOMA
    Cancer investigation
    
    C.J. Langer et al., "PHASE-II EVALUATION OF METHOTREXATE, VINBLASTINE, DOXORUBICIN, AND CISPLATIN (M-VAC) IN ADVANCED, MEASURABLE BREAST-CARCINOMA", Cancer investigation, 13(2), 1995, pp. 150-159
49. DANIEL V; BERGELSON S; PINKUS R; WEINER LM
    REDOX REGULATION OF AP-1 INDUCTION AND GLUTATHIONE-S-TRANSFERASE GENE-EXPRESSION
    Journal of cellular biochemistry
    
    V. Daniel et al., "REDOX REGULATION OF AP-1 INDUCTION AND GLUTATHIONE-S-TRANSFERASE GENE-EXPRESSION", Journal of cellular biochemistry, 1995, pp. 253-253
50. ALGAN O; COIA LR; KELLER SM; ENGSTROM PF; WEINER LM; SCHULTHEISS TE; HANKS GE
    MANAGEMENT OF ADENOCARCINOMA OF THE ESOPHAGUS WITH CHEMORADIATION ALONE OR CHEMORADIATION FOLLOWED BY ESOPHAGECTOMY - RESULTS OF SEQUENTIALNONRANDOMIZED PHASE-II STUDIES
    International journal of radiation oncology, biology, physics
    
    O. Algan et al., "MANAGEMENT OF ADENOCARCINOMA OF THE ESOPHAGUS WITH CHEMORADIATION ALONE OR CHEMORADIATION FOLLOWED BY ESOPHAGECTOMY - RESULTS OF SEQUENTIALNONRANDOMIZED PHASE-II STUDIES", International journal of radiation oncology, biology, physics, 32(3), 1995, pp. 753-761
51. ADAMS GP; MCCARTNEY JE; WOLF EJ; EISENBERG J; TAI MS; HUSTON JS; STAFFORD WF; BOOKMAN MA; HOUSTON LL; WEINER LM
    OPTIMIZATION OF IN-VIVO TUMOR TARGETING IN SCID MICE WITH DIVALENT FORMS OF 741F8 ANTI-C-ERBB-2 SINGLE-CHAIN FV - EFFECTS OF DOSE-ESCALATION AND REPEATED IV ADMINISTRATION
    Cancer immunology and immunotherapy
    
    G.P. Adams et al., "OPTIMIZATION OF IN-VIVO TUMOR TARGETING IN SCID MICE WITH DIVALENT FORMS OF 741F8 ANTI-C-ERBB-2 SINGLE-CHAIN FV - EFFECTS OF DOSE-ESCALATION AND REPEATED IV ADMINISTRATION", Cancer immunology and immunotherapy, 40(5), 1995, pp. 299-306
52. MCCARTNEY JE; TAI MS; HUDZIAK RM; ADAMS GP; WEINER LM; JIN D; STAFFORD WF; LIU S; BOOKMAN MA; LAMINET AA; FAND I; HOUSTON LL; OPPERMANN H; HUSTON JS
    ENGINEERING DISULFIDE-LINKED SINGLE-CHAIN FV DIMERS [(SFV')(2)] WITH IMPROVED SOLUTION AND TARGETING PROPERTIES - ANTIDIGOXIN-26-10 (SFV')(2) AND ANTI-C-ERBB-2 741F8 (SFV')(2) MADE BY PROTEIN-FOLDING AND BONDED THROUGH C-TERMINAL CYSTEINYL PEPTIDES
    Protein engineering
    
    J.E. Mccartney et al., "ENGINEERING DISULFIDE-LINKED SINGLE-CHAIN FV DIMERS [(SFV')(2)] WITH IMPROVED SOLUTION AND TARGETING PROPERTIES - ANTIDIGOXIN-26-10 (SFV')(2) AND ANTI-C-ERBB-2 741F8 (SFV')(2) MADE BY PROTEIN-FOLDING AND BONDED THROUGH C-TERMINAL CYSTEINYL PEPTIDES", Protein engineering, 8(3), 1995, pp. 301-314
53. HAAS NB; SCHILDER RJ; NASH S; WEINER LM; CATALANO RC; OZOLS RF; ODWYER PJ
    A PHASE-II TRIAL OF WEEKLY INFUSIONAL 5-FLUOROURACIL IN COMBINATION WITH LOW-DOSE LEUCOVORIN IN PATIENTS WITH ADVANCED COLORECTAL-CANCER
    Investigational new drugs
    
    N.B. Haas et al., "A PHASE-II TRIAL OF WEEKLY INFUSIONAL 5-FLUOROURACIL IN COMBINATION WITH LOW-DOSE LEUCOVORIN IN PATIENTS WITH ADVANCED COLORECTAL-CANCER", Investigational new drugs, 13(3), 1995, pp. 229-233
54. ADAMS GP; MCCARTNEY JE; WOLF EJ; EISENBERG J; HUSTON JS; BOOKMAN MA; MOLDOFSKY P; STAFFORD WF; HOUSTON LL; WEINER LM
    ENHANCED TUMOR SPECIFICITY OF 741F8-1(SFV')(2), AN ANTI-C-ERBB-2 SINGLE-CHAIN FV DIMER, MEDIATED BY STABLE RADIOIODINE CONJUGATION
    The Journal of nuclear medicine
    
    G.P. Adams et al., "ENHANCED TUMOR SPECIFICITY OF 741F8-1(SFV')(2), AN ANTI-C-ERBB-2 SINGLE-CHAIN FV DIMER, MEDIATED BY STABLE RADIOIODINE CONJUGATION", The Journal of nuclear medicine, 36(12), 1995, pp. 2276-2281
55. CLARK JI; WEINER LM
    BIOLOGIC TREATMENT OF HUMAN CANCER
    Current problems in cancer
    
    J.I. Clark e L.M. Weiner, "BIOLOGIC TREATMENT OF HUMAN CANCER", Current problems in cancer, 19(4), 1995, pp. 190-262
56. WEINER LM
    KRIGEL,ROBERT,L. MD (1949-1994) - IN-MEMORIAM
    Seminars in oncology
    
    L.M. Weiner, "KRIGEL,ROBERT,L. MD (1949-1994) - IN-MEMORIAM", Seminars in oncology, 22(3), 1995, pp. 201-201
57. ADAMS GP; WEINER LM
    INTRACELLULAR SINGLE-CHAIN FV ANTIBODIES - A KNOCKOUT PUNCH FOR NEOPLASTIC-CELLS
    Gynecologic oncology
    
    G.P. Adams e L.M. Weiner, "INTRACELLULAR SINGLE-CHAIN FV ANTIBODIES - A KNOCKOUT PUNCH FOR NEOPLASTIC-CELLS", Gynecologic oncology, 59(1), 1995, pp. 6-7
58. GEORGE AJT; JAMAR F; TAI MS; HEELAN BT; ADAMS GP; MCCARTNEY JE; HOUSTON LL; WEINER LM; OPPERMANN H; PETERS AM; HUSTON JS
    RADIOMETAL LABELING OF RECOMBINANT PROTEINS BY A GENETICALLY-ENGINEERED MINIMAL CHELATION SITE - TC-99M COORDINATION BY SINGLE-CHAIN FV ANTIBODY FUSION PROTEINS THROUGH A C-TERMINAL CYSTEINYL PEPTIDE
    Proceedings of the National Academy of Sciences of the United Statesof America
    
    A.J.T. George et al., "RADIOMETAL LABELING OF RECOMBINANT PROTEINS BY A GENETICALLY-ENGINEERED MINIMAL CHELATION SITE - TC-99M COORDINATION BY SINGLE-CHAIN FV ANTIBODY FUSION PROTEINS THROUGH A C-TERMINAL CYSTEINYL PEPTIDE", Proceedings of the National Academy of Sciences of the United Statesof America, 92(18), 1995, pp. 8358-8362
59. TAI MS; MCCARTNEY JE; ADAMS GP; JIN D; HUDZIAK RM; OPPERMANN H; LAMINET AA; BOOKMAN MA; WOLF EJ; LIU S; STAFFORD WF; FAND I; HOUSTON LL; WEINER LM; HUSTON JS
    TARGETING C-ERBB-2 EXPRESSING TUMORS USING SINGLE-CHAIN FV MONOMERS AND DIMERS
    Cancer research
    
    M.S. Tai et al., "TARGETING C-ERBB-2 EXPRESSING TUMORS USING SINGLE-CHAIN FV MONOMERS AND DIMERS", Cancer research, 55(23), 1995, pp. 5983-5989
60. WEINER LM; CLARK JI; DAVEY M; LI WS; DEPALAZZO IG; RING DB; ALPAUGH RK
    PHASE-I TRIAL OF 2B1, A BISPECIFIC MONOCLONAL-ANTIBODY TARGETING C-ERBB-2 AND FC-GAMMA-RIII
    Cancer research
    
    L.M. Weiner et al., "PHASE-I TRIAL OF 2B1, A BISPECIFIC MONOCLONAL-ANTIBODY TARGETING C-ERBB-2 AND FC-GAMMA-RIII", Cancer research, 55(20), 1995, pp. 4586-4593
61. SALEH MN; GOLDMAN SJ; LOBUGLIO AF; BEALL AC; SABIO H; MCCORD MC; MINASIAN L; ALPAUGH RK; WEINER LM; MUNN DH
    CD16(- SPONTANEOUS ELEVATION AND PHARMACOLOGICAL INDUCTION BY RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR() MONOCYTES IN PATIENTS WITH CANCER )
    Blood
    
    M.N. Saleh et al., "CD16(- SPONTANEOUS ELEVATION AND PHARMACOLOGICAL INDUCTION BY RECOMBINANT HUMAN MACROPHAGE-COLONY-STIMULATING FACTOR() MONOCYTES IN PATIENTS WITH CANCER )", Blood, 85(10), 1995, pp. 2910-2917
62. PINKUS R; WEINER LM; DANIEL V
    ROLE OF QUINONE-MEDIATED GENERATION OF HYDROXYL RADICALS IN THE INDUCTION OF GLUTATHIONE-S-TRANSFERASE GENE-EXPRESSION
    Biochemistry
    
    R. Pinkus et al., "ROLE OF QUINONE-MEDIATED GENERATION OF HYDROXYL RADICALS IN THE INDUCTION OF GLUTATHIONE-S-TRANSFERASE GENE-EXPRESSION", Biochemistry, 34(1), 1995, pp. 81-88
63. REDEI I; GREEN F; HOFFMAN JP; WEINER LM; SCHER R; ODWYER PJ
    PHASE-II TRIAL OF PALA AND 6-METHYLMERCAPTOPURINE RIBOSIDE (MMPR) IN COMBINATION WITH 5-FLUOROURACIL IN ADVANCED PANCREATIC-CANCER
    Investigational new drugs
    
    I. Redei et al., "PHASE-II TRIAL OF PALA AND 6-METHYLMERCAPTOPURINE RIBOSIDE (MMPR) IN COMBINATION WITH 5-FLUOROURACIL IN ADVANCED PANCREATIC-CANCER", Investigational new drugs, 12(4), 1994, pp. 319-321
64. SHPITZ B; CHAMBERS CA; SINGHAL AB; HOZUMI N; FERNANDES BJ; ROIFMAN CM; WEINER LM; RODER JC; GALLINGER S
    HIGH-LEVEL FUNCTIONAL ENGRAFTMENT OF SEVERE COMBINED IMMUNODEFICIENT MICE WITH HUMAN PERIPHERAL-BLOOD LYMPHOCYTES FOLLOWING PRETREATMENT WITH RADIATION AND ANTI-ASIALO G(M1)
    Journal of immunological methods
    
    B. Shpitz et al., "HIGH-LEVEL FUNCTIONAL ENGRAFTMENT OF SEVERE COMBINED IMMUNODEFICIENT MICE WITH HUMAN PERIPHERAL-BLOOD LYMPHOCYTES FOLLOWING PRETREATMENT WITH RADIATION AND ANTI-ASIALO G(M1)", Journal of immunological methods, 169(1), 1994, pp. 1-15
65. WEINER LM; LI W; HOLMES M; CATALANO RB; DOVNARSKY M; PADAVIC K; ALPAUGH RK
    PHASE-I TRIAL OF RECOMBINANT MACROPHAGE-COLONY-STIMULATING FACTOR ANDRECOMBINANT GAMMA-INTERFERON - TOXICITY, MONOCYTOSIS, AND CLINICAL EFFECTS
    Cancer research
    
    L.M. Weiner et al., "PHASE-I TRIAL OF RECOMBINANT MACROPHAGE-COLONY-STIMULATING FACTOR ANDRECOMBINANT GAMMA-INTERFERON - TOXICITY, MONOCYTOSIS, AND CLINICAL EFFECTS", Cancer research, 54(15), 1994, pp. 4084-4090
66. WEINER LM; HOLMES M; RICHESON A; GODWIN A; ADAMS GP; HSIEHMA ST; RING DB; ALPAUGH RK
    BINDING AND CYTOTOXICITY CHARACTERISTICS OF THE BISPECIFIC MURINE MONOCLONAL ANTIBODY-2B1
    The Journal of immunology
    
    L.M. Weiner et al., "BINDING AND CYTOTOXICITY CHARACTERISTICS OF THE BISPECIFIC MURINE MONOCLONAL ANTIBODY-2B1", The Journal of immunology, 151(5), 1993, pp. 2877-2886
67. ALPAUGH K; LI W; HOLMES M; WEINER LM
    SUSTAINED MONOCYTOSIS WITH INDUCED DIFFERENTIATED PHENOTYPE IN A PHASE-I STUDY OF RECOMBINANT MACROPHAGE-COLONY STIMULATING FACTOR AND RECOMBINANT GAMMA-INTERFERON
    The Journal of immunology
    
    K. Alpaugh et al., "SUSTAINED MONOCYTOSIS WITH INDUCED DIFFERENTIATED PHENOTYPE IN A PHASE-I STUDY OF RECOMBINANT MACROPHAGE-COLONY STIMULATING FACTOR AND RECOMBINANT GAMMA-INTERFERON", The Journal of immunology, 150(8), 1993, pp. 51-51
68. ADAMS GP; HUSTON JS; HOUSTON LL; FAND I; BOOKMAN MA; WEINER LM
    INVIVO TUMOR SPECIFICITY OF MONOMERIC AND DIMERIC FORMS OF THE 25 KD ANTI-C-ERBB-2 SINGLE-CHAIN FV (SFV) MOLECULE, 741F8
    The Journal of immunology
    
    G.P. Adams et al., "INVIVO TUMOR SPECIFICITY OF MONOMERIC AND DIMERIC FORMS OF THE 25 KD ANTI-C-ERBB-2 SINGLE-CHAIN FV (SFV) MOLECULE, 741F8", The Journal of immunology, 150(8), 1993, pp. 142-142
69. ADAMS GP; MCCARTNEY JE; TAI MS; OPPERMANN H; HUSTON JS; STAFFORD WF; BOOKMAN MA; FAND I; HOUSTON LL; WEINER LM
    HIGHLY SPECIFIC IN-VIVO TUMOR TARGETING BY MONOVALENT AND DIVALENT FORMS OF 741F8 ANTI-C-ERBB-2 SINGLE-CHAIN FV
    Cancer research
    
    G.P. Adams et al., "HIGHLY SPECIFIC IN-VIVO TUMOR TARGETING BY MONOVALENT AND DIVALENT FORMS OF 741F8 ANTI-C-ERBB-2 SINGLE-CHAIN FV", Cancer research, 53(17), 1993, pp. 4026-4034
70. DEPALAZZO IEG; ADAMS GP; SUNDARESHAN P; WONG AJ; TESTA JR; BIGNER DD; WEINER LM
    EXPRESSION OF MUTATED EPIDERMAL GROWTH-FACTOR RECEPTOR BY NONSMALL CELL LUNG CARCINOMAS
    Cancer research
    
    I.E.G. Depalazzo et al., "EXPRESSION OF MUTATED EPIDERMAL GROWTH-FACTOR RECEPTOR BY NONSMALL CELL LUNG CARCINOMAS", Cancer research, 53(14), 1993, pp. 3217-3220
71. FEINSTEIN E; CANAANI E; WEINER LM
    DEPENDENCE OF NUCLEIC-ACID DEGRADATION ON IN-SITU FREE-RADICAL PRODUCTION BY ADRIAMYCIN
    Biochemistry
    
    E. Feinstein et al., "DEPENDENCE OF NUCLEIC-ACID DEGRADATION ON IN-SITU FREE-RADICAL PRODUCTION BY ADRIAMYCIN", Biochemistry, 32(48), 1993, pp. 13156-13161
72. YELINOVA VI; WEINER LM; SLEPNEVA IA; LEVINA AS
    REVERSIBLE MODIFICATION OF CYSTEINE RESIDUES OF NADPH-CYTOCHROME-P-450 REDUCTASE
    Biochemical and biophysical research communications
    
    V.I. Yelinova et al., "REVERSIBLE MODIFICATION OF CYSTEINE RESIDUES OF NADPH-CYTOCHROME-P-450 REDUCTASE", Biochemical and biophysical research communications, 193(3), 1993, pp. 1044-1048
73. WOLDMAN YY; WEINER LM; LYAKHOVICH VV
    DIFFERENT STRUCTURE OF THE COMPLEXES OF 2 CYTOCHROME-P-450 ISOZYMES WITH ACETANILIDE BY H-1-NMR RELAXATION AND SPECTROPHOTOMETRY
    Biochemical and biophysical research communications
    
    Y.Y. Woldman et al., "DIFFERENT STRUCTURE OF THE COMPLEXES OF 2 CYTOCHROME-P-450 ISOZYMES WITH ACETANILIDE BY H-1-NMR RELAXATION AND SPECTROPHOTOMETRY", Biochemical and biophysical research communications, 193(1), 1993, pp. 40-46